17
Cost-effectiveness
data are emerging,
awaiting
outcomes for
primary therapy
maintenance
settings for poly
(ADP-ribose)
polymerase
inhibitor (PARPi)
Limited setting
recommendations
Basic setting
recommendations
No role for
targeted therapy
Focus on
symptom
management for
patients who are
extremely frail and
not fit for surgery/
have substantial
complications of
surgery, poor PS
>3, medically unfit
for chemotherapy
Targeted
therapy is NOT
recommended in
limited settings
on a routine basis
for patients with
stage IV
Assess patients
with stage IV
for appropriate
evidence-based
targeted therapy,
all patients with
high risk features,
and PS 0–2
Targeted
therapies are not
cost effective in
most resource-
constrained
regions unless
patients are
being treated
at enhanced or
maximal level
